Walleye Capital
PRQR icon

Walleye Capital’s ProQR Therapeutics PRQR Stock Holding History

Walleye Capital’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-607,529
Closed -$984K – 5088
2026
Q1 		$984K Buy
607,529
+15,744
+3% +$25.8K ﹤0.01% 2089
2025
Q4 		$1.2M Buy
591,785
+59,808
+11% +$140K ﹤0.01% 2291
2025
Q3 		$1.13M Hold
531,977
– – ﹤0.01% 1990
2025
Q2 		$1.09M Buy
531,977
+28,413
+6% +$46.2K ﹤0.01% 1982
2025
Q1 		$670K Buy
503,564
+52,261
+12% +$111K ﹤0.01% 2314
2024
Q4 		$1.2M Buy
+451,303
New +$1.43M ﹤0.01% 2219
2020
Q1 		– Sell
-11,393
Closed -$113K – 1501
2019
Q4 		$113K Buy
+11,393
New +$88.7K 0.01% 1329

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Walleye Capital's PRQR Position: Q2 2026 in Review

Walleye Capital sold out of ProQR Therapeutics (PRQR) in Q2 2026, closing a stake of 607,529 shares — an estimated $984K sold.

Walleye Capital first reported a position in PRQR in Q4 2019 and held it in 7 quarters. The position peaked at $1.2M in Q4 2024. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Walleye Capital reported no remaining ProQR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 607,529 ProQR Therapeutics shares in Q2 2026, an estimated $984K.
  • Walleye Capital first reported a position in ProQR Therapeutics in Q4 2019 and held it in 7 quarters.
  • Walleye Capital's ProQR Therapeutics position peaked at $1.2M in Q4 2024.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.